ADC Therapeutics SA announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA® in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first arm of the LOTIS-7 open-label, multi-center, multi-arm Phase 1b trial will evaluate the safety and activity of ZYNLONTA in combination with polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma. The trial will include multiple arms in two parts a dose escalation part and a dose expansion part.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 USD | -2.25% | -8.05% | +161.45% |
Apr. 09 | Transcript : ADC Therapeutics SA - Special Call | |
Apr. 04 | Sector Update: Health Care Stocks Slump Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+161.45% | 358M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics SA Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents